William Blair Comments on Agile Therapeutics Inc’s Q1 2020 Earnings (AGRX)

Share on StockTwits

Agile Therapeutics Inc (NASDAQ:AGRX) – Research analysts at William Blair issued their Q1 2020 earnings per share (EPS) estimates for shares of Agile Therapeutics in a note issued to investors on Wednesday, March 13th. William Blair analyst T. Lugo forecasts that the specialty pharmaceutical company will post earnings per share of ($0.12) for the quarter. William Blair also issued estimates for Agile Therapeutics’ Q2 2020 earnings at ($0.03) EPS, Q3 2020 earnings at $0.06 EPS and Q4 2020 earnings at $0.22 EPS.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04.

Other research analysts have also issued research reports about the company. Maxim Group reiterated a “buy” rating and issued a $3.00 target price on shares of Agile Therapeutics in a research report on Monday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Agile Therapeutics in a research report on Friday, January 11th. Finally, ValuEngine upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 11th.

Shares of AGRX opened at $1.61 on Thursday. The company has a market capitalization of $57.41 million, a PE ratio of -2.78 and a beta of 0.36. Agile Therapeutics has a 52 week low of $0.23 and a 52 week high of $3.24.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after buying an additional 18,038 shares in the last quarter. Geode Capital Management LLC boosted its position in Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the last quarter. Fosun International Ltd acquired a new stake in Agile Therapeutics during the third quarter valued at $180,000. Acadian Asset Management LLC lifted its position in shares of Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 226,255 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 54.3% in the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 430,907 shares during the last quarter. Institutional investors and hedge funds own 42.15% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: Buy-Side Analysts

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Surgery Partners Inc  Director Adam T. Feinstein Sells 7,865 Shares
Surgery Partners Inc Director Adam T. Feinstein Sells 7,865 Shares
Diamondback Energy  Given New $170.00 Price Target at Bank of America
Diamondback Energy Given New $170.00 Price Target at Bank of America
BT Group – CLASS A  Price Target Cut to GBX 325 by Analysts at Jefferies Financial Group
BT Group – CLASS A Price Target Cut to GBX 325 by Analysts at Jefferies Financial Group
ASGN Inc  Receives $74.43 Consensus PT from Brokerages
ASGN Inc Receives $74.43 Consensus PT from Brokerages
First Mercantile Trust Co. Buys New Holdings in Everbridge Inc
First Mercantile Trust Co. Buys New Holdings in Everbridge Inc
Intra-Cellular Therapies Inc  Holdings Boosted by First Mercantile Trust Co.
Intra-Cellular Therapies Inc Holdings Boosted by First Mercantile Trust Co.


© 2006-2019 Ticker Report